Literature DB >> 19372783

The CD4 lymphocyte count and risk of clinical progression.

Andrew N Phillips1, Jens D Lundgren.   

Abstract

PURPOSE OF REVIEW: The CD4 lymphocyte count was identified as a key predictor of risk of AIDS defining diseases almost 20 years ago, early in the HIV epidemic. Several issues concerning its use to predict AIDS have arisen since. These include the difference between short and long-term prediction, the use of CD4 percentage compared with absolute counts, the impact of antiretroviral therapy on the predictive value of the CD4 count, the role relative to other markers such as viral load, the derivation of scores to predict AIDS diseases, the use of CD4 count as a surrogate endpoint, the role of the CD4 count nadir compared with the current value and the differential ability to predict different AIDS diseases. RECENT
FINDINGS: All the above issues have been clarified further and this process has continued through 2004 and 2005. These developments are briefly described in this review.
SUMMARY: The CD4 count remains the strongest short-term predictor of risk of AIDS so far identified in both treated and untreated patients and should continue to be a mainstay of monitoring for both untreated and treated patients.

Entities:  

Year:  2006        PMID: 19372783     DOI: 10.1097/01.COH.0000194106.12816.b1

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  30 in total

Review 1.  A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Authors:  Josephine Mauskopf; Lieven Annemans; Andrew M Hill; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.

Authors:  Xavier Colin; Antoine Lafuma; Dominique Costagliola; Jean-Marie Lang; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Authors:  Andrew M Hill; Kelly Gebo; Lindsay Hemmett; Mickael Löthgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Authors:  Josephine Mauskopf; Anita Brogan; Silas Martin; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Laboratory Accuracy Improvement in the UK NEQAS Leucocyte Immunophenotyping Immune Monitoring Program: An Eleven-Year Review via Longitudinal Mixed Effects Modeling.

Authors:  John Bainbridge; Wes Rountree; Raul Louzao; John Wong; Liam Whitby; Thomas N Denny; David Barnett
Journal:  Cytometry B Clin Cytom       Date:  2017-05-16       Impact factor: 3.058

9.  Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.

Authors:  Anita J Brogan; Erik Smets; Josephine A Mauskopf; Sarah A L Manuel; Ines Adriaenssen
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

10.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.